Patents by Inventor Manuel Campos
Manuel Campos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230283378Abstract: The present invention relates to a dual GPON Small Form-Factor Pluggable optical module, projected to provide connection to two SC optical fiber connectors, and to be incorporated in any state of the art SFP transceiver host to allow double GPON-OLT channels. The module comprises a case housing a specific set of technical elements such as bidirectional optical subassemblies, high-speed electrical interface, and all the necessary electronic circuits, printed circuit board and flex-printed circuit board to ensure proper assembly and electronic performance of all elements.Type: ApplicationFiled: April 12, 2021Publication date: September 7, 2023Inventors: Cláudio Emanuel GOMES FERREIRINHO LIMA RODRIGUES, Paulo Jorge DA COSTA MÃO CHEIA, Joaquim Fernando VALE E SERRA, Tiago Manuel CAMPOS, Luis Miguel AMARAL HENRIQUES
-
Patent number: 10261092Abstract: Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive H. parasuis proteins. Also provided are compositions, vaccines, and kits using the molecules for diagnostics and methods for preventing or treating a disease, disorder, condition, or symptoms thereof associated with infectious agents, in particular infectious microorganisms, in particular for preventing or treating a disease, disorder, condition, or symptom thereof associated with H. parasuis infection.Type: GrantFiled: April 27, 2015Date of Patent: April 16, 2019Assignee: Elanco Tiergesundheit AGInventors: Thomas Plocher, Manuel Campos, Richard Harland, Todd Johnson, Trent Harbison, Dan Keil
-
Publication number: 20150293118Abstract: Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive H. parasuis proteins. Also provided are compositions, vaccines, and kits using the molecules for diagnostics and methods for preventing or treating a disease, disorder, condition, or symptoms thereof associated with infectious agents, in particular infectious microorganisms, in particular for preventing or treating a disease, disorder, condition, or symptom thereof associated with H. parasuis infection.Type: ApplicationFiled: April 27, 2015Publication date: October 15, 2015Applicant: NOVARTIS TIERGESUNDHEIT AGInventors: Thomas Plocher, Manuel Campos, Richard Harland, Todd Johnson, Trent Harbison, Dan Keil
-
Patent number: 9096554Abstract: The present invention relates to compounds with a benzoxadiazolyl amine structure which are capable of inhibiting the activation or the biological activity of p38 mitogen-activated protein kinase (MAPK) and the use thereof in the treatment of a disease that can be alleviated by means of inhibiting the activation or the biological activity of said p38 MAPK, for example, an inflammatory disease or a disease presenting with pain.Type: GrantFiled: October 31, 2012Date of Patent: August 4, 2015Assignee: UNIVERSIDAD AUTÓNOMA DE MADRIDInventors: Federico Mayor Menéndez, Cristina Murga Montesinos, Pedro Manuel Campos Muelas, Jacoba Johana Heijnen, Anna Maria Agnes Antonius Kavelaars, Antonio Morreale de León, Rubén Gil Redondo
-
Patent number: 9046528Abstract: Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive H. parasuis proteins. Also provided are compositions, vaccines, and kits using the molecules for diagnostics and methods for preventing or treating a disease, disorder, condition, or symptoms thereof associated with infectious agents, in particular infectious microorganisms, in particular for preventing or treating a disease, disorder, condition, or symptom thereof associated with H. parasuis infection.Type: GrantFiled: March 20, 2009Date of Patent: June 2, 2015Assignee: Novartis Tiergesundheit AGInventors: Thomas Plocher, Manuel Campos, Richard Harland, Todd Johnson, Trent Harbison, Dan Keil
-
Publication number: 20140296308Abstract: The present invention relates to compounds with a benzoxadiazolyl amine structure which are capable of inhibiting the activation or the biological activity of p38 mitogen-activated protein kinase (MAPK) and the use thereof in the treatment of a disease that can be alleviated by means of inhibiting the activation or the biological activity of said p38 MAPK, for example, an inflammatory disease or a disease presenting with pain.Type: ApplicationFiled: October 31, 2012Publication date: October 2, 2014Inventors: Federico Mayor Ménendez, Cristina Murga Montesinos, Pedro Manuel Campos Muelas, Jacoba Johana Heijnen, Anna Maria Agnes Antonius Kavelaars, Antonio Morreale de León, Rubén Gil Redondo
-
Publication number: 20120276282Abstract: A process of coating at least one substrate with a plurality of deposition sources, a method of tooling, a carrier unit and a deposition system are described. The systems and methods provide for or allow for exposing a first substrate portion 112a of said at least one substrate 112 to a first deposition source 118a through an aperture 122 of a carrier unit 110, 510, depositing a first layer 126a over the first substrate portion, said first layer including material from said first deposition source, varying a relative position between said at least one substrate and said aperture for exposing a second substrate portion of said at least one substrate, or another substrate, to a second deposition source, and depositing a second layer 126b over the second substrate portion 112b, said second layer including material from said second deposition source.Type: ApplicationFiled: May 10, 2011Publication date: November 1, 2012Applicant: APPLIED MATERIALS, INC.Inventors: Uwe HOFFMANN, Manuel CAMPO
-
Publication number: 20110014225Abstract: Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive H. parasuis proteins. Also provided are compositions, vaccines, and kits using the molecules for diagnostics and methods for preventing or treating a disease, disorder, condition, or symptoms thereof associated with infectious agents, in particular infectious microorganisms, in particular for preventing or treating a disease, disorder, condition, or symptom thereof associated with H. parasuis infection.Type: ApplicationFiled: March 20, 2009Publication date: January 20, 2011Applicant: NOVARTIS AGInventors: Thomas Plocher, Manuel Campos, Richard Harland, Todd Johnson, Trent Harbison, Dan Kiel
-
Publication number: 20100194287Abstract: An electronic ballast for an HID lamp is described, comprising: a rectifier circuit; a PFC power factor correction circuit increasing the direct current (DC) voltage coming out from the rectifier circuit; a current converter receiving the high voltage DC and converts it to alternating current (AC) to be supplied to the lamp; an ignition circuit generating ignition pulses being fed to the converter circuit to turn on the lamp, the pulses are generated by a downward frequencies scan, and, a control circuit commanding the operation of the ignition circuit and controlling the power being supplied to the lamp according to a power profile being determined by the lightning conditions desired to be obtained from said lamp to save energy. The operative method for the ballast is also described.Type: ApplicationFiled: January 29, 2008Publication date: August 5, 2010Inventors: Roberto Vivero-Flores, Alberto Manuel Campos-Violante
-
Publication number: 20080233097Abstract: A new phosphorylation site of mitogen-activated kinase proteins (MAPK) has been found. Phosphorylated MAPKs in said phosphorylation site can be used as a diagnostic marker of pathologies mediated by MAPKs.Type: ApplicationFiled: June 9, 2006Publication date: September 25, 2008Applicant: UNIVERSIDAD AUTONOMA DE MADRIDInventors: Cristina Murga Montesinos, Federico Mayor Menendez, Maria Jurado Pueyo, Pedro Manuel Campo Muelas, Sandra Peregrin Pedrique
-
Patent number: 6911206Abstract: The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a peptide endogenously synthesized within the vertebrate, the activity of which peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate; connected to (b) a second proteinaceous portion analogous to all or part of an immunogen from a pathogen, which pathogen is capable of pathogenically infecting the vertebrate; the portion (b) causing the vertebrate's immune system to recognize the portion (a) and produce a response that: (i) inhibits the activity of the peptide endogenously synthesized within the vertebrate; and (ii) protects the vertebrate from infection by the pathogen, when the vertebrate is vaccinated with an effective amount of the fusion protein.Type: GrantFiled: February 16, 2000Date of Patent: June 28, 2005Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Manuel Campos, Terecita D. Yule, Serge Martinod, Becky A. Durtschi
-
Publication number: 20050095258Abstract: The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a peptide endogenously synthesized within the vertebrate, the activity of which peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate; connected to (b) a second proteinaceous portion analogous to all or part of an immunogen from a pathogen, which pathogen is capable of pathogenically infecting the vertebrate; the portion (b) causing the vertebrate's immune system to recognize the portion (a) and produce a response that: (i) inhibits the activity of the peptide endogenously synthesized within the vertebrate; and (ii) protects the vertebrate from infection by the pathogen, when the vertebrate is vaccinated with an effective amount of the fusion protein.Type: ApplicationFiled: November 29, 2004Publication date: May 5, 2005Inventors: Manuel Campos, Terecita Yule, Serge Martinod, Becky Durtschi
-
Publication number: 20040223982Abstract: The present invention provides an homogenate prepared from cells of Neospora, and vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.Type: ApplicationFiled: June 21, 2004Publication date: November 11, 2004Inventors: David A. Brake, Manuel Campos
-
Publication number: 20040198954Abstract: The present invention is directed to five novel, low molecular weight proteins from Actinobacillus pleuropneumoniae (APP), which are capable of inducing, or contributing to the induction of, a protective immune response in swine against APP. The present invention is further directed to polynucleotide molecules having nucleotide sequences that encode the proteins, as well as vaccines comprising the proteins or polynucleotide molecules, and methods of making and using the same.Type: ApplicationFiled: February 3, 2004Publication date: October 7, 2004Inventors: Robert G. Ankenbauer, Mary Jo Baarsch, Manuel Campos, Robin Keich, Everett Rosey, Brian Suiter, Lynn Warren-Stewart
-
Patent number: 6787146Abstract: The present invention provides an homogenate prepared from cells of Neospora, and vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.Type: GrantFiled: November 9, 2001Date of Patent: September 7, 2004Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: David A. Brake, Manuel Campos
-
Patent number: 6713071Abstract: The present invention is directed to five novel, low molecular weight proteins from Actinobacillus pleuropneumoniae (APP), which are capable of inducing, or contributing to the induction of, a protective immune response in swine against APP. The present invention is further directed to polynucleotide molecules having nucleotide sequences that encode the proteins, as well as vaccines comprising the proteins or polynucleotide molecules, and methods of making and using the same.Type: GrantFiled: October 14, 1999Date of Patent: March 30, 2004Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Robert G. Ankenbauer, Mary Jo Baarsch, Manuel Campos, Robin Keich, Everett Rosey, Brian Suiter, Lynn Warren-Stewart
-
Publication number: 20020058046Abstract: The present invention provides an homogenate prepared from cells of Neospora, and vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.Type: ApplicationFiled: November 9, 2001Publication date: May 16, 2002Applicant: Pfizer Inc.Inventors: David A. Brake, Manuel Campos
-
Patent number: 6270800Abstract: A microencapsulated subunit component from bovine herpes virus-1 (BHV-1) is disclosed. Vaccines, kits, and methods for using the same to vaccinate a member of a bovine species are also disclosed.Type: GrantFiled: April 21, 1998Date of Patent: August 7, 2001Assignee: Pfizer Inc.Inventors: Tully J. Speaker, H. Fred Clark, Charlotte A. Moser, Paul A. Offit, Manuel Campos, Patrick J. Frenchick
-
Patent number: 6096320Abstract: New chimeric proteins, DNA encoding the same, and the use of these proteins in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are disclosed. The chimeric proteins include at least one epitope of an RTX cytotoxin fused to an active fragment of a cytokine. The chimeric proteins can be used in a vaccine composition. Also disclosed are methods of vaccination as well as methods of making the proteins employed in the vaccines.Type: GrantFiled: October 20, 1997Date of Patent: August 1, 2000Assignees: University of Saskatchewan, Ciba-Geigy Canada Ltd.Inventors: Andrew Potter, Manuel Campos, Huw P. A. Hughes
-
Patent number: 5594107Abstract: New chimeric proteins, DNA encoding the same, and the use of these proteins in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are disclosed. The chimeric proteins include at least one epitope of an RTX cytotoxin fused to an active fragment of a cytokine. The chimeric proteins can be used in a vaccine composition. Also disclosed are methods of vaccination as well as methods of making the proteins employed in the vaccines.Type: GrantFiled: December 20, 1993Date of Patent: January 14, 1997Assignees: University of Saskatchewan, Ciba-Geigy Canada Ltd.Inventors: Andrew Potter, Manuel Campos, Huw P. A. Hughes